AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 141 min read$LQDA

Moomaw Scott sold $252K of LQDA

Moomaw Scott (Chief Commercial Officer) sold 8,863 shares of Liquidia Corp (LQDA) at $28.48 ($0.25M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moomaw Scott
Published Oct 14, 2026, 12:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LQDA
Bearish
medium confidence
Mentioned
$LQDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDABearishLow
01

Why it matters

The disclosed sale is the primary new fact; no other material news is presented.

02

Market read

A modest insider sale by a senior officer, likely to cause limited short‑term price impact.

03

What to watch

Potential upcoming corporate developments could have prompted the timing of the sale.

Relevance 3/10Novelty 3/10Timing: after-hours

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$LQDABearishMedium confidence
Context

Chief Commercial Officer sold 8,863 shares for $252K via a 10b5-1 plan, reducing his holdings to 181,487 shares.

Expected impact

likely pressure as the market prices in the insider sell.

Evidence & confidence

C-suite insider sale, even modest, can be interpreted as reduced confidence and may prompt short-term downside.

Market effects

Sector

none

Regional

none

Global

none

Counterpoint

What could challenge this read

The sale may be routine under a pre‑arranged plan and not reflect negative sentiment.

Key entities

  • person
    Moomaw Scott

    Chief Commercial Officer of Liquidia Corp.

  • company
    Liquidia Corp

    Biopharmaceutical company listed on NASDAQ under LQDA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LQDA insider trading history →

Related articles

OCT 20
$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

news.alphastreet.com1 min
OCT 16
$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

biobuzz.io7 min
OCT 15
$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.

investing.com2 min